Meeting
2013 ASCO Annual Meeting
A phase I dose-escalation trial of AEZS-108 in taxane- and castration-resistant prostate cancer (CRPC).
Authors
Jacek K. Pinski
University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA
Jacek K. Pinski , Andrew V. Schally , Denice D Tsao-Wei , Tanya B. Dorff , Susan G. Groshen , Shigang Xiong , David I. Quinn , Yu-Chong Tai , Juergen Engel , Stephen V. Liu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT01240629
Citation
J Clin Oncol 31, 2013 (suppl; abstr 5062)
DOI
10.1200/jco.2013.31.15_suppl.5062
Abstract #
5062
Poster Bd #
38E
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Enzalutamide and metformin combination therapy to overcome autophagy resistance in castration resistant prostate cancer (CRPC): Current results from a phase I study.
First Author: Mamta Parikh
Poster
2012 Genitourinary Cancers Symposium
A phase I trial of AEZS-108 (AN-152) in castration- and taxane-resistant prostate cancer.
First Author: Stephen V. Liu
Poster
2023 ASCO Annual Meeting
Final results from phase I study of PSCA-targeted chimeric antigen receptor (CAR) T cells in patients with metastatic castration resistant prostate cancer (mCRPC).
First Author: Tanya B. Dorff
Poster
2023 ASCO Annual Meeting
Phase I dose-escalation results of prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT) with alpha-radiolabeled antibody 225Ac-J591 and beta-radioligand 177Lu-PSMA I&T.
First Author: Scott T. Tagawa